amyloidosis
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017
If approved, patisiran will be the first RNAi therapeutic on the market.